首页> 外文期刊>Anti-cancer drugs >MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair
【24h】

MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair

机译:MiR-199A通过与CCR7 / CCL21对的相互作用来介导人体地幔细胞淋巴瘤的传播

获取原文
获取原文并翻译 | 示例
           

摘要

Mantle cell lymphoma (MCL) is a rare but deadly subtype of non-Hodgkin's lymphomas because of it can progress rapidly and has a poor prognosis. MicroRNA-199a (miR-199a) is a potential diagnostic marker and therapeutic target for MCL patients. However, the function and molecular mechanisms of miRNA-199a in MCL cells are still unclear. In this study, we first analyzed the levels of miR-199a and C-C chemokine receptor 7 (CCR7) in the tumor tissues and tumor-adjacent tissues, and found that the level of miRNA-199a was lower, whereas the level of CCR7 was higher in tumor tissues. Moreover, overexpression of miR-199a in MCL cells downregulated the level of CCR7. Then, it was found that chemokine (C-C motif) ligand 21 (CCL21), a ligand of CCR7, promoted Granta-519 and Mino cell growth and migration in a concentration-dependent and time-dependent manner. Otherwise, the CCL21/CCR7 pair elevated the level of phosphorylation of protein kinase B and extracellular regulated protein kinases 1/2, upregulated the level of matrix metalloproteinases-2, matrix metalloproteinases-9, and the markers of the mesenchymal phenotype (N-cadherin and vimentin), as well as decreased the level of E-cadherin. However, the functions of CCL21/CCR7 in the growth, migration, and dissemination of MCL cells were decreased by overexpression of miR-199a. Thus, miR-199a inhibited the dissemination of MCL cells by reversing the function of CCL21/CCR7, providing a theoretical basis for miRNA-199a as a potential novel diagnostic marker and therapeutic target for MCL patients. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
机译:地幔细胞淋巴瘤(MCL)是非霍奇金淋巴瘤的罕见但致命的亚型,因为它可以迅速发展并且预后差。 MicroRNA-199A(MiR-199A)是MCL患者的潜在诊断标记和治疗靶标。然而,MiRNA-199A在MCL细胞中的功能和分子机制仍然不清楚。在这项研究中,我们首先分析了肿瘤组织和肿瘤邻近组织中MiR-199A和CC趋化因子受体7(CCR7)的水平,发现MiRNA-199A的水平较低,而CCR7的水平较高在肿瘤组织中。此外,MIR-199A在MCL细胞中的过度表达下调了CCR7的水平。然后,发现趋化因子(C-C基序)配体21(CCL21),CCR7的配体,以浓度依赖性和时间依赖的方式促进Granta-519和Mino细胞生长和迁移。否则,CCL21 / CCR7对升高了蛋白激酶B和细胞外调节蛋白激酶1/2的磷酸化水平,上调了基质金属蛋白酶-2,基质金属蛋白酶-9和间充质表型的标志物(n-cadherin和平节),以及降低E-cadherin的水平。然而,通过MIR-199A的过表达降低了CCL21 / CCR7在生长,迁移和传播中的功能的功能。因此,MIR-199A通过反转CCL21 / CCR7的功能来抑制MCL细胞的传播,为MiRNA-199A提供理论基础,作为MIRNA-199A作为MCL患者的潜在新型诊断标志物和治疗靶标。版权所有(c)2018 Wolters Kluwer Health,Inc。保留所有权利。

著录项

  • 来源
    《Anti-cancer drugs》 |2018年第9期|共10页
  • 作者单位

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Nursing Zhengzhou Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Dept Oncol Sci Ave 100 Zhengzhou 450001 Henan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药品;
  • 关键词

    CCL21; C-C chemokine receptor 7; dissemination; invasion; mantle cell lymphoma; miR-199a;

    机译:CCL21;C-C趋化因子受体7;传播;侵袭;地幔细胞淋巴瘤;MIR-199A;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号